The aim of this work was to give clinical practice recommendations on the use of tumour necrosis factor blocking agents in psoriatic arthritis, underlining the pathogenetic mechanism of this condition and its articular and dermatologic manifestations. We retrace the stages leading to the therapeutic indications of biological agents that are presently used in the treatment of psoriatic arthritis: Entanercept, Adalimumab, Infliximab. We also report our personal experience describing an emblematic case of a patient with psoriatic arthritis in which a decisive regression of joint/skin involvement was obtained with Infliximab treatment.
Infliximab treatment in Psoriatic Arthritis: our experience / TROISE RIODA, Valter; Adorni, G.. - In: ACTA BIO-MEDICA DE L'ATENEO PARMENSE. - ISSN 0392-4203. - 77:(2006), pp. 95-102.
Infliximab treatment in Psoriatic Arthritis: our experience
TROISE RIODA, Valter;
2006-01-01
Abstract
The aim of this work was to give clinical practice recommendations on the use of tumour necrosis factor blocking agents in psoriatic arthritis, underlining the pathogenetic mechanism of this condition and its articular and dermatologic manifestations. We retrace the stages leading to the therapeutic indications of biological agents that are presently used in the treatment of psoriatic arthritis: Entanercept, Adalimumab, Infliximab. We also report our personal experience describing an emblematic case of a patient with psoriatic arthritis in which a decisive regression of joint/skin involvement was obtained with Infliximab treatment.| File | Dimensione | Formato | |
|---|---|---|---|
|
Inflizimab.pdf
non disponibili
Tipologia:
Documento in Post-print
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
566.5 kB
Formato
Adobe PDF
|
566.5 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
